BIIB-122市場：市場規模、予測、新たな洞察-2032年

BIIB-122は、ロイシンリッチリピートキナーゼ2（LRRK2）に対する選択的な中枢神経透過性低分子阻害剤であり、パーキンソン病の基礎生物学に影響を与え、進行を遅らせることを目的とした新規ターゲットとなることができます。LRRK2の阻害は、パーキンソン病に関与する根本的な生物学的経路を標的とした新しいアプローチです。LRRK2活性はパーキンソン病で亢進し、ライソゾーム機能を負に制御します。LRRK2の阻害はライソゾーム機能を回復させ、タンパク質プロセッシングを正常化します。

現在、LRRK2遺伝子変異を有するパーキンソン病患者を対象とした第III相LIGHTHOUSE試験および第IIb相LUMA試験で評価中です。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、BIIB-122の優位性に影響を与える可能性のある機会を模索しています。他のパーキンソン病治療薬もBIIB-122と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のBIIB-122市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるBIIB-122の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 BIIB-122市場評価

• パーキンソン病におけるBIIB-122市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療におけるBIIB-122の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: BIIB-122, Clinical Trial Description, 2023
• Table 2: BIIB-122, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: BIIB-122 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: BIIB-122 Market Size in the US, in USD million (2019-2032)
• Table 7: BIIB-122 Market Size in Germany, in USD million (2019-2032)
• Table 8: BIIB-122 Market Size in France, in USD million (2019-2032)
• Table 9: BIIB-122 Market Size in Italy, in USD million (2019-2032)
• Table 10: BIIB-122 Market Size in Spain, in USD million (2019-2032)
• Table 11: BIIB-122 Market Size in the UK, in USD million (2019-2032)
• Table 12: BIIB-122 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: BIIB-122 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: BIIB-122 Market Size in the United States, USD million (2019-2032)
• Figure 3: BIIB-122 Market Size in Germany, USD million (2019-2032)
• Figure 4: BIIB-122 Market Size in France, USD million (2019-2032)
• Figure 5: BIIB-122 Market Size in Italy, USD million (2019-2032)
• Figure 6: BIIB-122 Market Size in Spain, USD million (2019-2032)
• Figure 7: BIIB-122 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: BIIB-122 Market Size in Japan, USD million (2019-2032)

"BIIB-122 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BIIB-122 for Parkinson's disease in the seven major markets. A detailed picture of the BIIB-122 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BIIB-122 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BIIB-122 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

BIIB-122 is a selective, central nervous system-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), a potential novel target intended to impact the underlying biology and slow the progression of Parkinson's disease. Inhibition of LRRK2 is a novel approach designed to target an underlying biological pathway implicated in Parkinson's disease. LRRK2 activity is increased in Parkinson's disease and negatively regulates lysosomal function; LRRK2 inhibition rescues lysosomal function and normalizes protein processing.

Presently the drug is being evaluated in a Phase III LIGHTHOUSE trial and a Phase IIb LUMA trial in individuals with Parkinson's disease with LRRK2 pathogenic variants.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the BIIB-122 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on BIIB-122 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BIIB-122 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around BIIB-122.
• The report contains forecasted sales of BIIB-122 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for BIIB-122 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BIIB-122 Analytical Perspective by DelveInsight

• In-depth BIIB-122 Market Assessment

This report provides a detailed market assessment of BIIB-122 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• BIIB-122 Clinical Assessment

The report provides the clinical trials information of BIIB-122 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BIIB-122 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to BIIB-122 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BIIB-122 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of BIIB-122 from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BIIB-122 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of BIIB-122?
• What is the clinical trial status of the study related to BIIB-122 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BIIB-122 development?
• What are the key designations that have been granted to BIIB-122 for Parkinson's disease?
• What is the forecasted market scenario of BIIB-122 for Parkinson's disease?
• What are the forecasted sales of BIIB-122 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to BIIB-122 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. BIIB-122 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. BIIB-122 Market Assessment

• 5.1. Market Outlook of BIIB-122 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of BIIB-122 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of BIIB-122 in the United States for Parkinson's disease
  • 5.3.2. Market Size of BIIB-122 in Germany for Parkinson's disease
  • 5.3.3. Market Size of BIIB-122 in France for Parkinson's disease
  • 5.3.4. Market Size of BIIB-122 in Italy for Parkinson's disease
  • 5.3.5. Market Size of BIIB-122 in Spain for Parkinson's disease
  • 5.3.6. Market Size of BIIB-122 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of BIIB-122 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options